Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: Carmel M. Hawley Clear advanced filters

  • In 2024, a plethora of novel therapeutic strategies for kidney disease progressed to clinical trials, including an RNA interference therapeutic, a glucagon-like peptide 1 receptor agonist, a soluble guanylate cyclase activator and an off-the-shelf, virus-specific T cell therapy. These advances herald new hope for people with kidney disease.

    • Monica Suet Ying Ng
    • Carmel M. Hawley
    News & Views
    Nature Reviews Nephrology
    Volume: 21, P: 75-76

  • Although the relationship between asymptomatic hyperuricemia and chronic kidney disease is not fully understood, data from small studies indicate that reducing high serum urate level may slow disease progression. In this Perspectives article, Badve and colleagues propose that a multicenter pilot randomized controlled trial be performed to investigate the effects of uric-acid-lowering therapy in patients with CKD.

    • Sunil V. Badve
    • Fiona Brown
    • Vlado Perkovic
    Reviews
    Nature Reviews Nephrology
    Volume: 7, P: 295-300

  • Drug repurposing could expand the therapeutic options available to patients with glomerular disease. Here, the authors examine different approaches to the identification of drug candidates, consider current immunosuppressive and non-immunological options and discuss strategies to maximize drug repurposing in glomerular disease.

    • Monica Suet Ying Ng
    • Gursimran Kaur
    • David W. Johnson
    Reviews
    Nature Reviews Nephrology
    Volume: 20, P: 707-721